Company Profile

Inventage Lab Inc is a Korea-based company principally engaged in the pharmaceutical business. The Company owns the platforms applied to the development and mass production of long-acting injections and drug delivery of genetic materials. The Company is engaged in the research, manufacture and sale of human medicines used for male pattern baldness, dementia, prostate cancer and others. It is also engaged in the research, manufacture and sale of veterinary medicines such as combination drugs, chemical castration agents and others.

Employees

Sector

Pharmaceuticals

Calendar

Mar. 24 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
26-01-16	80,600.00 ₩	-0.86%	118,949
26-01-15	81,300.00 ₩	+1.37%	76,310
26-01-14	80,200.00 ₩	-4.07%	131,351
26-01-13	83,600.00 ₩	-3.80%	129,562
26-01-12	86,900.00 ₩	-0.11%	106,198

End-of-day quote Korea S.E., January 15, 2026

More quotes

End-of-day quote Korea S.E. Other stock markets 2026-01-16			5-day change	1st Jan Change
80,600.00 ^KRW	-0.86%		-7.36%	-4.28%

Dec. 10	Inventage Lab Seeks Approval for Phase 2 Trial of Alopecia Drug in Australia	MT
25-09-22	Inventage Lab, Inc.(KOSDAQ:A389470) added to S&P Global BMI Index	CI

Dec. 10	Inventage Lab Seeks Approval for Phase 2 Trial of Alopecia Drug in Australia	MT
25-09-22	Inventage Lab, Inc.(KOSDAQ:A389470) added to S&P Global BMI Index	CI
25-03-11	Inventage Lab, Inc. announced that it has received KRW 9.9999925 billion in funding from PEACE to S KOREA Co., Ltd	CI
25-03-11	Quratis Inc. announced that it has received KRW 10.0329 billion in funding from Inventage Lab, Inc.	CI
25-02-20	Quratis Inc. announced that it has received KRW 15 billion in funding from Inventage Lab, Inc.	CI
25-01-14	Inventage Lab, Inc. announced that it has received KRW 4.8 billion in funding	CI
25-01-12	Inventage Lab, Inc. announced that it expects to receive ZAR 9.9999925 billion in funding	CI
25-01-12	Inventage Lab, Inc. announced that it expects to receive KRW 4.8 billion in funding	CI
24-11-24	Quratis Inc. announced that it expects to receive KRW 10.0329 billion in funding from Inventage Lab, Inc.	CI
24-10-30	Quratis Inc. announced that it expects to receive KRW 15 billion in funding from Inventage Lab, Inc.	CI
24-09-19	Inventage Lab, Inc. announced that it has received KRW 39 billion in funding	CI
24-09-12	Inventage Lab, Inc. announced that it expects to receive KRW 39 billion in funding	CI
23-06-18	Inventage Lab, Inc. announced that it has received KRW 18.49998452 billion in funding from The Korea Securities Finance Corporation, Shinhan Bank	CI

1 day	-0.86%
1 week	-7.36%
Current month	-4.28%
1 month	-7.89%
3 months	+114.36%
6 months	+149.54%
Current year	-4.28%

1 week	75,500	88,600
1 month	69,500	91,000
Current year	75,500	90,500
1 year	12,100	99,000
3 years	8,440	99,000
5 years	8,440	99,000
10 years	8,440	99,000

Inventage Lab, Inc. Stock

Equities

A389470

KR7389470006

Pharmaceuticals

Chart: Inventage Lab, Inc.

Latest news: Inventage Lab, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Inventage Lab, Inc.

Other Pharmaceuticals

Company Profile

Quotes

Manager	Title	Age	Since
Ju-Hee Kim CEO	Chief Executive Officer	52	2015-05-13
Chan-Hee Jeon CTO	Chief Tech/Sci/R&D Officer	57	-
Choong-Ho Ryu PRN	Corporate Officer/Principal	56	-

Director	Title	Age	Since
Ju-Hee Kim BRD	Director/Board Member	52	2015-05-13
Choong-Ho Ryu BRD	Director/Board Member	56	-
Chan-Hee Jeon BRD	Director/Board Member	57	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
INVENTAGE LAB, INC.	-0.86%	-7.36%	+326.00%	+762.03%	683M
ELI LILLY AND COMPANY	+0.53%	-2.37%	+37.06%	+187.15%	930B
JOHNSON & JOHNSON	-0.41%	+6.98%	+47.97%	+26.08%	527B
ABBVIE INC.	-0.31%	-2.60%	+23.40%	+39.55%	379B
ROCHE HOLDING AG	+0.93%	+2.38%	+29.90%	+18.43%	371B
ASTRAZENECA PLC	+0.19%	-1.15%	+29.58%	+20.35%	292B
MERCK & CO., INC.	-1.93%	-1.54%	+8.07%	-3.05%	270B
NOVARTIS AG	+0.98%	+1.37%	+27.61%	+34.08%	276B
NOVO NORDISK A/S	+6.49%	+1.95%	-35.37%	-18.36%	268B
AMGEN INC.	+0.12%	+1.32%	+22.63%	+21.59%	178B
Average	+0.57%	-0.09%	+51.69%	+108.79%	349.16B
Weighted average by Cap.	+0.59%	+0.50%	+26.61%	+64.02%